1. |
|
|
2. |
|
|
3. |
|
|
4. |
|
|
5. |
- Rönnevig, Marit, et al.
(författare)
-
Patients´ experiences for living with irritable bowel syndrome
- 2009
-
Ingår i: Journal of Advanced Nursing. - : Wiley. - 1365-2648 .- 0309-2402. ; 65:8, s. 1676-1685
-
Tidskriftsartikel (refereegranskat)abstract
- Aim. This paper is a report of a study conducted to describe people’s experiences, and meanings of these, while living with irritable bowel syndrome. Background. Irritable bowel syndrome is characterized by abdominal pain, diarrhoea and/or constipation, distension and bloating. Such symptoms are stigmatized in western societies. Patients may experience negative attitudes from healthcare personnel, and they can feel helpless and frustrated trying to control symptoms. Method. A qualitative, hermeneutic approach was used. Open-ended interviews were conducted during 2005–2006 with 13 patients currently diagnosed with irritable bowel syndrome. The interview setting was a rural healthcare centre or the person’s home. An interpretive analysis of the data was performed. Findings. Four interwoven themes were identified in the data: Living with unpredictability, represented by the subthemes ‘not being in control’, ‘not being able to trust’ and ‘invasion of privacy’; preserving dignity, described by ‘living with sacrifice’, ‘taking command’ and ‘fulfilling obligations’; ‘reconciling struggle’; and ‘living with comorbidity’. Conclusion. The unpredictability and taboos of irritable bowel syndrome made these people suffer, feel constrained and dependent. Dignity was preserved both by sacrifices and taking command. Healthcare personnel should allow patients to talk about their suffering and discomfort to decrease their experience of suffering. Our study contributes to a more nuanced understanding of life with this unpleasant companion, the suffering it creates and the threats to dignity and health.
|
|
6. |
- Schnell, O, et al.
(författare)
-
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
- 2022
-
Ingår i: Cardiovascular diabetology. - : Springer Science and Business Media LLC. - 1475-2840. ; 21:1, s. 50-
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year’s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1–5, and STEP 1–5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed.Trial registrationThe 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10–11, 2022 (http://www.cvot.org)
|
|
7. |
|
|
8. |
|
|